AUTHORS
Mathias Palmer, MD, Mohamad Sheikh Najeeb2, Ajoy Dias, M.B.B.S.3, Tariq Kewan, MD4, Aasiya Matin, MBBS5, Mehrdad Hefazi Torghabeh, MD6, Abhishek Avinash Mangaonkar, MBBS7, Hassan B Alkhateeb, M.D.8, Mithun Shah, MD, PhD9, Mrinal M. Patnaik, MD, MBBS10, Naseema Gangat, MBBS11, William Hogan, M.B., B.Ch.12, Mark R. Litzow, MD13, Cecilia Arana Yi, M.D.14, James Foran, FRCPC15, Antoine N. Saliba, M.D.16, Kebede Begna, M.D.17, Aref Al-Kali, M.D.18
AFFILIATIONS
1 Mayo Clinic, Jacksonville, Florida, United States
2 Mayo Clinic, Jacksonville, Florida, United States
3 Mayo Clinic, Jacksonville, Florida, United States
4 Mayo Clinic, Jacksonville, Florida, United States
5 Mayo Clinic, Jacksonville, Florida, United States
6 Mayo Clinic, Jacksonville, Florida, United States
7 Mayo Clinic, Jacksonville, Florida, United States
8 Mayo Clinic, Jacksonville, Florida, United States
9 Mayo Clinic, Jacksonville, Florida, United States
10 Mayo Clinic, Jacksonville, Florida, United States
11 Mayo Clinic, Jacksonville, Florida, United States
12 Mayo Clinic, Jacksonville, Florida, United States
13 Mayo Clinic, Jacksonville, Florida, United States
14 Mayo Clinic, Jacksonville, Florida, United States
15 Mayo Clinic, Jacksonville, Florida, United States
16 Mayo Clinic, Jacksonville, Florida, United States
17 Mayo Clinic, Rochester, Minnesota, United States
18 Mayo Clinic, Rochester, Minnesota, United States
ABSTRACT
Introduction: Hypomethylating agents (HMA) plus venetoclax (HMA/VEN) are now standard of care for patients with AML ineligible for intensive chemotherapy (IC). In 2024, favorable risk was defined by ELN as AML with mutations of DDX41, IDH1, IDH2, and NPM1. Mutations in the transcription factor CCAAT/enhancer-binding protein-alpha (CEBPA) have been associated with favorable outcomes in patients treated with IC, but less is known about outcomes following treatment with HMA/VEN.
In this single-institution retrospective review, we compared outcomes of patients treated with HMA/VEN to patients treated with chemotherapy and to CEBPA-negative patients meeting ELN 2024 favorable-risk criteria.
Methods: Patients treated at Mayo Clinic Rochester with CEBPA-mutated AML or classified as “favorable risk” per ELN 2024 criteria between 2016 and 2024 were identified. Median overall survival (mOS) and median relapse-free survival (mRFS) were assessed by Kaplan-Meier methodology. Chemotherapy included any combination of cytarabine and anthracycline with or without a targeted inhibitor. CEBPA mutations were subdivided into bZIP in-frame insertion/deletion/duplication, bZIP missense mutation, bZIP frameshift mutation, N-terminal region mutations, and other CEBPA mutations outside of bZIP domain. Successful induction was defined as achievement of CR, CRi, CRh, or MLFS. Relapse-free survival was defined as time from treatment initiation to relapse or death; patients with primary refractory disease were excluded from relapse-free survival analysis. All statistics were calculated using BlueSky Statistics Version 10.3.4.
Results: Among 625 patients with AML, 43 had CEBPA mutations, 15 (35%) treated with HMA/VEN and 19 (44%) treated with IC. The remaining patients received HMA monotherapy (3, 7%), HMA plus FLT3 inhibitor (1, 2%), IDH2 inhibitor (1, 2%), or did not receive treatment (4, 9%). A total of 136 patients had favorable risk disease per ELN 2024 criteria and were CEBPA negative. Compared with patients treated with IC, those receiving HMA/VEN were older (median age, 69 vs 55 years; P<0.01) and less likely to undergo allogeneic transplantation (20% vs 68%; p<0.01). Rates of secondary AML, therapy-related AML, complex karyotype, and chromosome 7 abnormalities were not significantly different between cohorts. Most mutations were in the N-terminal (63%) followed by other non-bZIP mutations (33%), bZIP frameshift (21%), bZIP missense (14%), and bZIP in-frame insertion/deletion/duplication (14%). There were no bZIP in-frame insertion/deletion/duplication events in patients treated with HMA/VEN. Rates of biallelic CEBPA mutations were similar in HMA/VEN and IC cohorts (20% vs 32%, p=0.7).
Successful induction was achieved in most patients (HMA/VEN 80%, IC 89%, p=0.63) with high rates of CR/CRi (HMA/VEN 67%, IC 89%, p=0.20). MRD testing rates were low but MRD negative rates were high in HMA/VEN (8 of 9 tested, 89%) and IC (5 of 7 tested, 71%). Relapse rates were higher in HMA/VEN compared to IC, but did not reach statistical significance (75% vs 53%, p=0.27). Compared to IC, mRFS (8.8 vs 51.7 months, p=0.04) and mOS (12.0 vs 92.5 months, p< 0.01) were significantly shorter with HMA/VEN. When censoring for allo-HSCT, mOS was longer in HMA/VEN compared with IC, but did not reach statistical significance (9.8 months vs 5.8 months, p=0.5). In patients treated with HMA/VEN, biallelic CEBPA mutation had higher mRFS (9.7 vs 7.9 months, p=0.62) and lower mOS (11 vs 12.5 months, p=0.79) compared to monoallelic mutation. In patients treated with IC, mRFS and mOS were not reached for patients with biallelic CEBPA mutation.
Median RFS and mOS did not differ significantly between patients treated with HMA/VEN and CEBPA-negative patinets meeting ELN 2024 favorable-risk criteria (mRFS 8.8 vs 11.1 months, p=0.39; mOS 12.0 vs 17 months, p=0.67), but this analysis could be unpowered.
Conclusion: Patients with CEBPA-mutated AML treated with HMA/VEN achieved initial remission rates comparable to those treated with IC. Median RFS and mOS were significantly shorter in the HMA/VEN cohort compared to the IC cohort, although interpretation is limited due to differences in age, disease risk distribution, and transplant utilization. Rates of classic in-frame CEBPA bZIP insertions/deletions/duplications were uncommon in patients treated with HMA/VEN, suggesting the distribution of CEBPA mutation subtypes may differ in older and IC-ineligible populations.
DISCLOSURES
Mathias Palmer, MD: No relevant conflicts of interest to declare.